Keros Therapeutics, Inc. ( (KROS) ) has released its Q4 earnings. Here is a breakdown of the information Keros Therapeutics, Inc. presented to its investors.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins, which play a crucial role in tissue growth and maintenance. The company is at the forefront of creating protein therapeutics with potential disease-modifying benefits.
In its latest earnings report, Keros Therapeutics highlighted significant business developments and financial results for the fourth quarter and full year of 2024. The company reported a strengthened cash position due to a $200 million upfront payment from a licensing agreement with Takeda Pharmaceuticals, which is expected to support its operations until 2029.
Key financial metrics from the report include a net loss of $46.0 million for the fourth quarter and $187.4 million for the full year, driven by increased research and development expenses. Revenue for 2024 was $3.6 million, a notable increase from the previous year, primarily due to a milestone achieved under a license agreement with Hansoh Healthtech.
Despite the losses, Keros continues to advance its pipeline with ongoing clinical trials, including the Phase 1 trial of KER-065 and the Phase 2 TROPOS trial for cibotercept. The company is also progressing with the development of elritercept for treating low blood cell counts.
Looking ahead, Keros Therapeutics remains focused on advancing its clinical trials and evaluating development strategies for its product candidates, with a solid financial foundation to support its long-term goals.